StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.41+0.06 (+4.44%)

Close on Nov 17, 2026Market cap $1.43MP/E –Yield –

Transcode Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Transcode Therapeutics's price to book ratio was 3.3× on Jul 31, 2026, against 25.2× a year earlier.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 20263.3×−0.7
2025Dec 31, 20254.0×−323.9
2024Jul 31, 2024327.9×–

More Transcode Therapeutics figures

See a number that looks wrong?